New research from Karolinska Institutet suggests that the blockbuster drug semaglutide—the active ingredient in Ozempic—may have a profound secondary effect beyond diabetes and obesity treatment: drastically reducing sick leave and the need for mental health care. For Nordic businesses and policymakers grappling with soaring healthcare costs and workforce attrition, this finding signals a potential paradigm shift.
A comprehensive observational study tracking over 95,000 Swedes between 2009 and 2022 revealed that patients with pre-existing anxiety or depression who took semaglutide had a 42 percent lower risk of sick leave or requiring mental health care compared to periods when they were not on the medication. While liraglutide showed a modest 18 percent reduction, other GLP-1 drugs like exenatide and dulaglutide showed no significant effect.
A Question of Causality—and Opportunity
Because the study is observational, it cannot definitively establish causality. However, the implications are too significant for the Nordic business sector to ignore. Professor Jari Tiihonen of Karolinska Institutet notes two possible mechanisms: the psychological benefit of improved physical health (weight loss and diabetes management) or a direct biological effect on the brain, potentially reducing inflammation and stress hormones.
For business leaders, the analysis extends beyond clinical outcomes. Nordic countries, with their robust social safety nets, bear a heavy financial burden from long-term sick leave and mental health-related absenteeism. If semaglutide can demonstrably reduce these risks, it moves from being a pharmaceutical expense to a potential workforce stability investment.
An Update for Current Times: The Broader Nordic Context
Since the study period concluded in 2022, the landscape has shifted dramatically. Ozempic and similar GLP-1 agonists have faced supply shortages across the Nordics due to soaring off-label demand for weight loss. Furthermore, this spring, the European Medicines Agency (EMA) concluded a prolonged safety review into reports of suicidal ideation associated with GLP-1 drugs—a review sparked by preliminary concerns that this new research directly contradicts.
While the EMA found no causal link, the Nordic Business Journal notes that this creates a complex risk-reward calculus for employers and insurers. The Karolinska data offers a counter-narrative: for patients with depression and anxiety, these drugs may be protective rather than harmful.
Strategic Analysis for Nordic Stakeholders
1. For Employers and HR Leaders: Self-insured Nordic corporations and municipal employers should watch for upcoming randomized controlled trials (RCTs) that could confirm causality. A 42% reduction in mental health-related sick leave would dramatically alter the ROI of including these expensive drugs in occupational health benefits.
2. For Insurers and Pension Funds: If these findings hold, we may see a reclassification of GLP-1 drugs from lifestyle or diabetes treatments to preventive mental health care. This could expand reimbursement models under social insurance systems like Sweden’s Försäkringskassan or Norway’s NAV.
3. For Investors: The divergence in efficacy between semaglutide and older GLP-1 drugs (exenatide, dulaglutide) highlights the importance of next-generation compounds. Pharmaceutical companies with assets targeting neuroinflammation may find new market opportunities in the psychiatry space.
Professor Tiihonen emphasizes that confirmation requires randomised controlled trials, which are currently the missing link. Until then, the Nordic business community must treat this as a high-probability signal rather than a certainty.
Follow-Up Direction
In our next issue, we will explore the ethical and economic dilemmas facing Nordic employers: Should companies subsidise expensive GLP-1 medications proactively to reduce long-term absenteeism, and how should they navigate the fine line between clinical intervention and workforce optimisation?
Connect with us
For deeper analysis on how emerging biotech trends are reshaping the Nordic labour market and healthcare economy, join our subscriber network at Nordic Business Journal or follow our editorial team on LinkedIn for weekly insights.